Personalized mRNA vaccine boosts melanoma immunotherapy
You can also search for this author in PubMed Google Scholar
Adjuvant checkpoint inhibitor therapy is the standard of care for resectable melanoma. Although many patients derive lasting benefit from the treatment, a substantial number experience disease recurrence.
Precision medicine meets cancer vaccines
CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial
Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial
Read more research highlights selected by the Nature Medicine team
/https%3A%2F%2Ftf-cmsv2-smithsonianmag-media.s3.amazonaws.com%2Ffiler_public%2F73%2F5c%2F735ce030-bc9a-4925-a4da-4eaa225bc873%2Fgettyimages-1413268947.jpg)
